WO2013116624A1 - Matériaux fibreux alignés présentant orientation de fibres variant dans l'espace et procédés associés - Google Patents

Matériaux fibreux alignés présentant orientation de fibres variant dans l'espace et procédés associés Download PDF

Info

Publication number
WO2013116624A1
WO2013116624A1 PCT/US2013/024313 US2013024313W WO2013116624A1 WO 2013116624 A1 WO2013116624 A1 WO 2013116624A1 US 2013024313 W US2013024313 W US 2013024313W WO 2013116624 A1 WO2013116624 A1 WO 2013116624A1
Authority
WO
WIPO (PCT)
Prior art keywords
population
fibers
composition
polymeric
layer
Prior art date
Application number
PCT/US2013/024313
Other languages
English (en)
Inventor
Robert L. Mauck
Matthew B. FISHER
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2013116624A1 publication Critical patent/WO2013116624A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
    • B32B5/02—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by structural features of a fibrous or filamentary layer
    • B32B5/12—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by structural features of a fibrous or filamentary layer characterised by the relative arrangement of fibres or filaments of different layers, e.g. the fibres or filaments being parallel or perpendicular to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/38—Joints for elbows or knees
    • A61F2/3872—Meniscus for implantation between the natural bone surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442—Intervertebral or spinal discs, e.g. resilient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A61L27/3891—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types as distinct cell layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/02—Layered products comprising a layer of synthetic resin in the form of fibres or filaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30009—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in fibre orientations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/3094—Designing or manufacturing processes
    • A61F2002/30971—Laminates, i.e. layered products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442—Intervertebral or spinal discs, e.g. resilient
    • A61F2002/4435—Support means or repair of the natural disc wall, i.e. annulus, e.g. using plates, membranes or meshes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2002/4495—Joints for the spine, e.g. vertebrae, spinal discs having a fabric structure, e.g. made from wires or fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Definitions

  • the present disclosure relates to the fields of biocompatible implant materials and to biocompatible polymer fibers.
  • the menisci are crescent-shaped fibrocartilaginous tissues that function to transmit and distribute loads between the femur and tibia of the knee joint. As such, the meniscus experiences complex loads, including tension, compression, and shear. Meniscus function in tension arises from an organized microstructure - bundles of highly aligned collagen circumnavigate the tissue between insertion sites on the tibial plateau. These aligned collagen bundles endow the tissue with mechanical properties that are highly anisotropic, and highest in the primary collagen orientation.
  • Existing meniscus replacement materials lack this unique structure and organization.
  • musculoskeletal system including the knee meniscus and the annulus fibrosus (AF) of the intervertebral disc, are prone to failure and have a limited reparative capacity once damaged.
  • Both tissues are ordered hierarchical laminates: the knee meniscus has a preponderance of circumferential collagen bundles with interspersed, perpendicularly directed, 'tie' fibers, while the AF consists of multiple alternating layers of oriented (+/- about 30°) collagen fibers that form an angle-ply structure.
  • the mechanical function of both tissues arises at least in part from this underlying fibrous architecture.
  • This disclosure also presents data concerning the structure and mechanics of nanofibrous scaffolds collected using this novel technique, as compared to compare to aligned scaffolds obtained from a traditional electrospinning approach. Without being bound to any particular theory, one may hypothesize that these circumferentially aligned (CircAl) scaffolds would behave similarly to linearly aligned (LinAl) scaffolds on short length scales, but exhibit marked differences in mechanics as the length scale increased.
  • This disclosure presents aligned nanofibrous scaffolds (formable from a variety of polymers) that can mimic the order of these native tissues, and direct cell and matrix organization with in vitro culture. Also disclosed are constructed biologic laminates, in which scaffold layers are fused with one another through cell mediated matrix-deposition with appositional culture.
  • Clinical application of these materials may, in some cases, benefit from implantation of already formed acellular multi-lamellar constructs.
  • a 'spot-welding' method has been previously described in which method individual layers are bound together through local scaffold melting brought on by contacting at least one of the layers with a heated probe. This approach creates stable bi-layers, but can cause compression of the construct with insertion of the heated probes or arrays of probes.
  • FIG. 7 An example of spot-welded layers is shown in Figure 7. That figure illustrates insertion of a heated probe into two adjacent layers so as to fuse them together.
  • the number of spot welds (lower left of figure) affects the mechanical properties of the final material, but the macroscopic structure of the spot- welded layers (lower left of figure) is affected by insertion of the heated probe.
  • a new method for forming nanofibrous laminates using light responsive materials which materials may be polymeric fibers having nanoscale bodies (e.g., gold nanorods) disposed within.
  • the nanoscale bodies effect controlled levels of heat with exposure to near-infrared (IR) light, which in turn allows for fusion of layers without physical contact from a probe or other instrument. This lack of contact in turn allows for layer fusion without the disruption of the layers' underlying structure that may result from contacting the layers with thermal probes or other implements.
  • IR near-infrared
  • the present disclosure provides laminates, the laminates comprising a first layer comprising a first population of polymeric fibers, at least some of the first population of polymeric fibers comprising nanoscale bodies disposed within; and a second layer comprising a second population of polymeric fibers, the first and second layers being bonded together at one or more locations.
  • the present disclosure also provides methods, the methods comprising irradiating a first fibrous layer comprising a first population of polymeric fibers having a first population of nanoscale bodies disposed within, the irradiating being performed so as to bond at least a portion of the first layer to a second fibrous layer comprising a second population of polymeric fibers.
  • compositions comprising a first layer comprising a first population of polymeric fibers, the first population of polymeric fibers having an anisotropic alignment that varies spatially within the layer.
  • implants comprising a quantity of a composition according to the present disclosure, the quantity of material being shaped to as to approximate at least a portion of a knee meniscus, an annulus fibrosis, or any combination thereof.
  • compositions according to the present disclosure comprising seeding a composition according to the present disclosure with a population of cells.
  • Figure 3 presents A) Bright field images of fibers collected on slides (4x). B) Plot of mean fiber angle as a function of position from center of scaffold;
  • Figure 5 presents A) Schematic of specimens taken for tensile testing from circumferentially aligned (CA) mats. B) Modulus of CA and linearly aligned specimens with varying radii (3cm, 5cm), sample length (short, long) and region for strain analysis (center, edge). (*p ⁇ 0.05 between short and long groups, +p ⁇ 0.05 between scaffold region). C)
  • Figure 6 illustrates the annulus fibrosis and the meniscus, two fibrous tissues
  • Figure 7 illustrates an existing method of forming a multi-lamellar nanofibrous structure
  • Figure 8 illustrates a micrograph of an annulus fibrosis and also an image of a meniscus replacement material
  • Figure 9 illustrates exemplary parameters used in an experiment involving dispersion of gold nanorods in poly-caprolactone polymer
  • Figure 10 illustrates an exemplary process for fabricating multilamellar materials according to the present disclosure
  • Figure 1 1 illustrates exemplary results realized from fabricating multilamellar materials according to the present disclosure
  • Figure 12 illustrates capro lactone nanofiber morphology without (left) and with (right) inclusionof gold nanorods within the nanofibers;
  • Figure 13 illustrates a less-magnified view of Figure 12
  • Figure 14 illustrates the morphology of a fibrous material made from polycaprolactone fibers after spot welding (left) and nanorod-infrared welding (right);
  • Figure 15 illustrates mechanical data obtained from testing fibrous scaffolds without (“PCL”) and with (“NRS”) nanorods;
  • Figure 16 illustrates interface strength achieved by materials according to the present disclosure
  • Figure 17 presents cell viability and morphology results obtained on fibrous polycaprolactone scaffolds without (PCL) and with (NRS) nanorod incusion;
  • Figure 18 depicts an exemplary method of fabricating anatomic meniscus structures according to the present disclosure.
  • Figure 19 depicts (A) a schematic showing electrospinning of fibers onto a rotating mandrel; (B) and (C) bright field images of strips of angled fibers with magnified images showing local alignment.
  • Figure 20 illustrates a meniscus showing (A) the generalized anatomic macrostructure and (B) a wedge-like cross-section displaying a simplified collagen fiber organization, with the majority of fiber bundles in the circumferential direction with occasional radial "tie" fibers.
  • Figure 21 schematically illustrates an exemplary electrospinning set-up, anticipated fiber direction, and map of the linear velocity on the mandrel surface designed to produce (A) linearly aligned and (B) circumferentially aligned scaffolds.
  • Figure 23 presents the mechanical properties of LinAl and CircAl scaffolds.
  • A Schematic showing lengths of scaffolds tested (short, long) and regions of analysis (center, edge).
  • B Color maps of Lagrangian strain in the testing direction (E yy ) within individual regions.
  • C Quantification of the tangent modulus,
  • D strain along the direction of loading (Eyy), and
  • E shear strain (E xy ). *P ⁇ 0.01 between short and long scaffolds, + P ⁇ 0.01 between center and edge regions.
  • Figure 24 presents a model of theoretical fiber deposition.
  • A Typical simulations of fiber populations for LinAl and CircAl fibers. Scale bar 10 mm.
  • B Comparison of fiber appearance between model-generated and bright field images of experimental samples.
  • FIG. 25 presents, in table form, exemplary mechanical properties of CircAl and LinAl scaffolds.
  • the present disclosure provides laminates.
  • the laminates suitably include a first layer comprising a first population of polymeric fibers, with at least some of the first population of polymeric fibers comprising nanoscale bodies disposed within.
  • the laminates suitably include a second layer comprising a second population of polymeric fibers, and the first and second layers are suitably bonded together at one or more locations.
  • the first population of polymeric fibers may comprise virtually any polymer.
  • Polymers that are natural, synthetic, biocompatible, biodegradable, non-biodegradable, bioabsorbable, or any combination thereof are all suitable. It should be understood that in some embodiments, e.g., when an electrospun material is made of a single fiber (e.g. nanofiber), the fiber is folded thereupon, hence can be viewed as a plurality of connected fibers. It is to be understood that a more detailed reference to a plurality of fibers is not intended to limit the scope of the present disclosure to such particular case. Thus, unless otherwise defined, any reference herein to a "plurality of fibers" applies also to a single fiber and vice versa.
  • the cross-sections of the fiber or fibers may be circular, oval, rectangular, square, or any shape which can be defined by the spinneret.
  • the fibers can have a cross-sectional dimension in the range of about 1 nm to about 10 microns, in the range of about 20 nm to about 1000 nm, in the range of about 100 nm to about 1000 nm, or in the range of about 1 micron to about 10 microns.
  • Fibers may be polymer fibers having diameters typically between 10 nm and 1000 nm. Exemplary sub-ranges contemplated by the present disclosure include between 100 and 1000 nm between 100 and 800 nm, between 100 and 600 nm, and between 100 and 400 nm. Other exemplary ranges include 10-100 nm, 10-200 nm and 10-500 nm. As mentioned, the fibers of the present disclosure are preferably generated by an electrospinning processes. In certain preferred embodiments, the first population of fibers, the second population of fibers, or both, has an average cross-sectional dimension in the range of from about 10 nm to about 10,000 nm.
  • the various fibers may comprise materials that are natural, synthetic, biocompatible, biodegradable, non-biodegradable, and/or biosorbable, and unless specifically restricted to one or more of these categories, the fibers may comprise materials from any one of these categories.
  • synthetic polymer refers to polymers that are not found in nature, even if the polymers are made from naturally occurring biomaterials. Examples include, but are not limited to, aliphatic polyesters, poly(amino acids), copoly(ether- esters), polyalkylenes oxalates, polyamides, tyrosine derived polycarbonates, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes, polysiloxanes, and combinations thereof.
  • Suitable synthetic polymers for use according to the present disclosure may include biosynthetic polymers based on sequences found in collagen, elastin, thrombin, fibronectin, starches, poly(amino acid), poly(propylene fumarate), gelatin, alginate, pectin, fibrin, oxidized cellulose, chitin, chitosan, tropoelastin, hyaluronic acid, polyethylene, polyethylene terephthalate, poly(tetrafluoroethylene), polycarbonate, polypropylene and poly(vinyl alcohol), ribonucleic acids, deoxyribonucleic acids, polypeptides, proteins, polysaccharides, polynucleotides and combinations thereof.
  • the phrase "natural polymer” refers to polymers that are naturally occurring. Non-limiting examples of such polymers include, silk, collagen-based materials, chitosan, hyaluronic acid and alginate.
  • biocompatible polymer refers to any polymer (synthetic or natural) which when in contact with cells, tissues or body or physiological fluid of an organism does not induce adverse effects such as immunological reactions and/or rejections and the like. It will be appreciated that a biocompatible polymer can also be a biodegradable polymer.
  • biodegradable polymer refers to a synthetic or natural polymer which can be degraded (i.e., broken down) in the physiological environment such as by enzymes, microbes, or proteins. Biodegradability depends on the availability of degradation substrates (i.e., biological materials or portion thereof which are part of the polymer), the presence of biodegrading materials (e.g., microorganisms, enzymes, proteins) and the availability of oxygen (for aerobic organisms, microorganisms or portions thereof), carbon dioxide (for anaerobic organisms, microorganisms or portions thereof) and/or other nutrients.
  • degradation substrates i.e., biological materials or portion thereof which are part of the polymer
  • biodegrading materials e.g., microorganisms, enzymes, proteins
  • oxygen for aerobic organisms, microorganisms or portions thereof
  • carbon dioxide for anaerobic organisms, microorganisms or portions thereof
  • Aliphatic polyesters poly(amino acids), polyalkylene oxalates, polyamides, polyamido esters, poly(anhydrides), poly(beta-amino esters), polycarbonates, polyethers, polyorthoesters, polyphosphazenes, and combinations thereof are considered biodegradable.
  • biodegradable polymers include, but are not limited to, collagen (e.g., Collagen I or IV), fibrin, hyaluronic acid, polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), poly(Lactide-co- Glycolide) (PLGA), polydioxanone (PDO), trimethylene carbonate (TMC), polyethyleneglycol (PEG), Collagen, PEG-DMA, alginate or alginic acid, chitosan polymers, or copolymers or mixtures thereof.
  • collagen e.g., Collagen I or IV
  • fibrin hyaluronic acid
  • PLA polylactic acid
  • PGA polyglycolic acid
  • PCL polycaprolactone
  • PDO poly(Lactide-co- Glycolide)
  • TMC trimethylene carbonate
  • PEG polyethyleneglycol
  • Collagen PEG-DMA
  • alginate or alginic acid chitosan
  • non-biodegradable polymer refers to a synthetic or natural polymer which is not degraded (i.e., broken down) in the physiological environment.
  • non-biodegradable polymers include, but are not limited to, carbon, nylon, silicon, silk, polyurethanes, polycarbonates, polyacrylonitriles, polyanilines, polyvinyl carbazoles, polyvinyl chlorides, polyvinyl fluorides, polyvinyl imidazoles, polyvinyl alcohols, polystyrenes and poly(vinyl phenols), aliphatic polyesters, polyacrylates, polymethacrylates, acyl-sutostituted cellulose acetates, nonbiodegradable polyurethanes, polystyrenes, chlorosulphonated polyolefins, polyethylene oxides, polytetrafluoroethylenes, polydialkylsiloxanes, and shape-memory materials such as poly (styrene), poly(vinyrene
  • biosorbable refers to those polymers which are absorbed within the host body, either through a biodegradation process, or by simple dissolution in aqueous or other body fluids.
  • Water soluble polymers such as poly(ethylene oxide) are included in this class of polymers.
  • the scaffold may be fabricated from a copolymer.
  • co-polymer refers to a polymer of at least two chemically distinct monomers.
  • Non-limiting examples of co-polymers which may be used to fabricate the scaffolds of the present disclosure include, PLA-PEG, PEGT-PBT, PLA-PGA, PEG-PCL and PCL-PLA.
  • the use of copolymers or mixtures of polymers / copolymers provides a flexible means of providing the required blend of properties.
  • functionalized poly(p-amino esters) which may be formed by the conjugate addition of primary or secondary amines with diacrylates, can provide a range of materials exhibiting a wide array of advantageous properties for this purpose. Such materials are described, for example, in
  • compositions may be comprised of a mixture of simultaneously or sequentially delivered polymers and / or copolymers. This includes mixtures of at least two natural, synthetic, biocompatible, biodegradable, non-biodegradable, and / or biosorbable polymers and co-polymers.
  • compositions comprises two or more fibers, that each may have a different biodegradation and / or biosorption profile in a physiological fluid, said fluids including water, saline, simulated body fluid, or synovial fluid.
  • the polymers, co-polymers, or blends thereof may be photolytically active, such that once electrospun, they may be made to crosslink on exposure to light, thereby improving the tensile characteristics of the scaffold, and increasing the diversity and range of properties available. See for example, Tan, et ah, J. Biomed Matl. Res., vol. 87 (4), 2008, pp. 1034-1043, which is incorporated by reference in its entirety.
  • the first layer, the second layer, or both further comprises a porogenic material. At least part of the porogenic material may be present as fibers, particles, or any combination thereof.
  • the term "porogen” refers to sacrificial materials added during the production of a scaffold (for example, during electrospinning) and subsequently removed, whose purpose is to occupy space during the construction process, such that their subsequent removal results in what amounts to engineered porosity.
  • tissue engineering materials such as inorganic salt like sodium chloride, crystals of saccharose, gelatin spheres or paraffin spheres are used to introduce particulate porosity.
  • the use of porogen fibers provides, in some embodiments, porosity aligned with the remaining fibers.
  • the second population of fibers may include a population of nanoscale bodies disposed within.
  • a nanoscale body may be organic, inorganic (e.g., metallic).
  • a nanoscale body may also be a biological molecule, such as a growth factor, a protease, trypsin, and the like.
  • a variety of dopants may be present within (or on) the fibers of the disclosed materials.
  • these dopants include at least one therapeutic compound or agent, capable of modifying cellular activity.
  • agents that act to increase cell attachment, cell spreading, cell proliferation, cell differentiation and/or cell migration in the scaffold may also be incorporated into the scaffold.
  • agents can be biological agents such as an amino acid, peptides, polypeptides, proteins, DNA, RNA, lipids and/or proteoglycans.
  • These agents may also include growth factors [e.g., a epidermal growth factor, a transforming growth factor-a, a basic fibroblast growth factor, a fibroblast growth factor-acidic, a bone morphogenic protein, a fibroblast growth factor-basic, erythropoietin, thrombopoietin, hepatocyte growth factor, insulin-like growth factor-I, insulin-like growth factor-II, Interferon- ⁇ , platelet- derived growth factor, a nerve growth factor, a transforming growth factor, a tumor necrosis factor, Vascular Endothelial Growth Factor, an angiopeptin, or a homolog or combination thereof], cytokines [e.g., M-CSF, IL-lbeta, IL-8, beta-thromboglobulin, EMAP-II, G-CSF and IL-IO, or a homolog or combination thereof], proteases [pepsin, low specificity chymotry
  • Suitable proteins which can be used along with the present disclosure include, but are not limited to, extracellular matrix proteins [e.g., fibrinogen, collagen, fibronectin, vimentin, microtubule-associated protein ID, Neurite outgrowth factor (NOF), bacterial cellulose (BC), laminin and gelatin], cell adhesion proteins [e.g., integrin, proteoglycan,
  • glycosaminoglycan laminin, intercellular adhesion molecule (ICAM) 1, N-CAM, cadherin, tenascin, gicerin, RGD peptide and nerve injury induced protein 2 (ninjurin2)].
  • IAM intercellular adhesion molecule 1
  • N-CAM N-CAM
  • cadherin tenascin
  • gicerin gicerin
  • RGD nerve injury induced protein 2
  • the materials of the present disclosure may comprise an antiproliferative agent (e.g., rapamycin, paclitaxel, tranilast, Atorvastatin and trapidil), an immunosuppressant drug (e.g., sirolimus, tacrolimus and Cyclosporine) and/or a non-thrombogenic or anti-adhesive substance (e.g., tissue plasminogen activator, reteplase, TNK-tPA, glycoprotein Ilb/IIIa inhibitors, clopidogrel, aspirin, heparin and low molecular weight heparins such as enoxiparin and dalteparin).
  • an antiproliferative agent e.g., rapamycin, paclitaxel, tranilast, Atorvastatin and trapidil
  • an immunosuppressant drug e.g., sirolimus, tacrolimus and Cyclosporine
  • immunosuppressive agents which can be used to minimize immunosuppression include, but are not limited to, methotrexate, cyclophosphamide, cyclosporine, cyclosporin A, chloroquine, hydroxychloroquine, sulfasalazine
  • sulphasalazopyrine gold salts
  • D-penicillamine leflunomide
  • azathioprine anakinra
  • infliximab REMICADE
  • etanercept TNF-a
  • blockers a biological agent that targets an inflammatory cytokine, IL-1 receptor antagonists, and Non-Steroidal Anti-Inflammatory Drug (NSAIDs).
  • NSAIDs Non-Steroidal Anti-Inflammatory Drug
  • NSAIDs include, but are not limited to acetyl salicylic acid, choline magnesium salicylate, diflunisal, magnesium salicylate, salsalate, sodium salicylate, diclofenac, etodolac, fenoprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, naproxen, nabumetone, phenylbutazone, piroxicam, sulindac, tolmetin, acetaminophen, ibuprofen, Cox-2 inhibitors and tramadol.
  • Cytokines useful in the present disclosure include, but are not limited to, cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MOP-1 alpha, 2, 3 alpha, 3 beta, 4, and 5, IL-, 11-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF-a, and TNF- ⁇ .
  • Immunoglobulins useful in the present disclosure include but are not limited to, IgG, IgA, IgM, IgD, IgE, and mixtures thereof.
  • Some preferred growth factors include VEGF (vascular endothelial growth factor), NGFs (nerve growth factors), PFGF-AA, PDGF-BB, PDGF-AB, FGFb, FGFa, and BGF.
  • the disclosed materials may include a single type of nanoscale body/dopant, or two or more types of nanoscale bodies/ dopants.
  • a nanoscale body suitably has at least one cross-sectional dimension in the range of from about 1 nm to about 100 nm.
  • a cross-sectional dimension is a length, width, diameter, or thickness.
  • a nanoscale body suitably has an aspect ratio in the range of from about 1 to about 100.
  • a nanorod having a height of 10 nm and a diameter of 5 nm would be considered suitable.
  • a nanorod having a diameter in the range of from about 2 to about 4 nm and a length in the range of from about 7 nm to about 9 nm is considered an especially suitable nanoscale body, particularly when the nanorod is made of gold.
  • At least a portion of the first population of fibers are suitably substantially aligned in a first direction. It should be understood that not all of the first population of fibers need be aligned in this first direction. It is preferable that more than 50% of the fibers be aligned in this first direction, but 50% should not be understood as being a particular threshold.
  • at least a portion of the second population of fibers are substantially aligned in a second direction. The first a second directions may be parallel to one another, although parallel directions are not a requirement.
  • at least a portion of the second population of fibers is aligned perpendicular to at least a portion of the first population of fibers. In this way, the perpendicular fibers may act as tie fibers in an artificial meniscus material.
  • At least a portion of the first population of fibers, at least a portion of the second population of fiber, or both, have an arcuate alignment.
  • Arcuate should be understood as referring to fibers that are curved (as opposed to being straight).
  • the curve may be a circular or circumferential one, although other curves (e.g., elliptical or other curves that are not based on a constant radius) are also suitable.
  • FIG. 3 shows linearly aligned fibers (Figure 3A) and circumferentially-aligned fibers (Figure 3B).
  • Figure 3C illustrates the mean fiber angle (degrees) as a function of the fiber's position from the center of the mandrel. Data are shown for linearly-aligned fibers (which have an unchanging fiber angle) and for circularly- aligned fibers (which have an angle that changes as a function of the fiber's distance from the center of the mandrel).
  • the first population of fibers, the second population of fibers, or both, may have an anisotropic alignment.
  • the compositions have a fiber alignment that varies spatially within the body of the composition. This is described below in additional detail.
  • At least some of the first population of fibers may differ from at least some of the second population of fibers in composition, cross-sectional dimension, or both.
  • some of the first population of fibers may have an average diameter of about 100 nm
  • some of the second population of fibers may have an average diameter of about 150 nm.
  • the first population may be formed from a first biocompatible polymer
  • the second population may be formed from a second, different biocompatible polymer.
  • At least one of the first layer and the second layer has a population of cells disposed thereon.
  • populations of cells can exist within the composition as homogeneous or heterogeneous mixtures, and as at least one gradient either across a radial and axial/longitudinal distance, or both. These gradients can be continuous or step-wise, as with the other components, as determined by the processing parameters.
  • the cells may be seeded directly onto the scaffold, or alternatively, the cells may be mixed with a gel which is then absorbed onto the interior and exterior surfaces of the scaffold and which may fill some of the pores of the scaffold. Capillary forces will retain the gel on the scaffold before hardening, or the gel may be allowed to harden on the scaffold to become more self-supporting.
  • the cells may be combined with a cell support substrate in the form of a gel optionally including extracellular matrix components.
  • the cells which can be used according to the teachings of the present disclosure may comprise non-autologous cells or non-autologous cells (e.g. allogeneic cells or xenogeneic cells), such as from human cadavers, human donors or xenogeneic (e.g. porcine) donors.
  • non-autologous cells or non-autologous cells e.g. allogeneic cells or xenogeneic cells
  • xenogeneic e.g. porcine
  • the cells may comprise a heterogeneous population of cells or alternatively the cells may comprise a homogeneous population of cells.
  • Such cells can be, for example, stem cells (such as adipose derived stem cells, embryonic stem cells, bone marrow stem cells, cord blood cells, mesenchymal stem cells, adult tissue stem cells, induced pluripotential stem cells,), progenitor cells (e.g.
  • progenitor bone cells progenitor bone cells
  • differentiated cellarrays such as chondrocytes, meniscal fibrochondrocytes, osteoblasts, osteoclasts, osteocytes, connective tissue cells (e.g., fibrocytes, fibroblasts, tenocytes, and adipose cells), endothelial and epithelial cells, or mixtures thereof.
  • stem cell refers to cells which are capable of differentiating into other cell types having a particular, specialized function (i.e., “fully differentiated” cells) or remaining in an undifferentiated state hereinafter “pluripotent stem cells”.
  • such cells may be of autologous origin or non-autologous origin, such as postpartum-derived cells (as described in U.S. Application Nos. 10/887,012 and 10/887,446). Cells may be selected according to the tissue being generated.
  • certain embodiments comprise industrial applications, including dimensionally shaped filters, textile, composites, catalyst scaffolds, electrolytic cell diaphragms, battery separators, and fuel cell components.
  • the fibrous material also comprises a catalyst, including biological catalysts, for example, but not limited to, enzymes, anti-microbials, or anti-fungals.
  • a catalyst including biological catalysts, for example, but not limited to, enzymes, anti-microbials, or anti-fungals.
  • the means for incorporating these catalysts onto or within electrospun materials are well known in the art as being analogous to those used to incorporate particles as described above.
  • the means for functionalizing, immobilizing and/or attaching catalysts onto polymer materials are equally known to those skilled in the art.
  • the first and second layers may have different populations of cells disposed thereon. As an example, the first layer may include stem cells, and the second layer may include connective tissue cells.
  • the present disclosure also provides methods. These methods include irradiating a first fibrous layer comprising a first population of polymeric fibers having a first population of nanoscale bodies disposed within, the irradiating being performed so as to bond at least a portion of the first layer to a second fibrous layer comprising a second population of polymeric fibers.
  • irradiating causing local heating at or around the nanoscale bodies so as to bond the first and second fibrous layer together at or near to the site of the irradiation. It should be understood that the first and second layers may both contain populations of nanoscale bodies.
  • Suitable nanoscale bodies are described elsewhere herein. As explained above, a nanoscale body suitably has at least one cross-sectional dimension in the range of from about 1 nm to about 100 nm, or even in the range of from about 10 nm to about 50 nm.
  • the irradiating may be effected by lasing, suitably by an infrared laser.
  • An exemplary laser is described elsewhere herein.
  • the user of ordinary skill in the art will be equipped to select a laser of a suitable wavelength to effect the desired local heating.
  • a user may dispose the first population of nanoscale bodies within a polymeric fluid so as to form a first mixture and then electrospin the first population of polymeric fibers from the first mixture. Additional information concerning electronspinning is presented elsewhere herein.
  • a user may further dispose the second population of nanoscale bodies within a polymeric fluid so as to form a second mixture and then form the second population of polymeric fibers (e.g., via electrospinning) from the second mixture.
  • the populations of polymeric fibers may be, as described elsewhere herein, formed from one or more material that is natural, synthetic, biocompatible, biodegradable, nonbiodegradable, biosorbable, or some combination thereof.
  • the first population of fibers, the second population of fibers, or both has an average cross-sectional dimension in the range of from about 10 nm to about 10,000 nm, or in the range of from about 100 nm to about 1000 nm, or from about 200 nm to about 500 nm.
  • the first population of polymeric fibers, the second population of polymeric fibers, or both may be characterized as being an anisotropic alignment of fibers.
  • the fiber alignment may be linear, but may also be arcuate, as described elsewhere herein.
  • at least some of the fibers in the first layer have a different alignment than some of the fibers of the second layer.
  • at least some of the fibers in the second layer are oriented essentially perpendicular to at least some of the fibers of the first layer.
  • Figure 9 presents exemplary process conditions for a fibrous layer that contains nanoscale bodies.
  • nanoscale gold nanorods may be disposed within a polymer.
  • Application of radiation e.g., laser
  • Figure 10 presents an exemplary scheme for forming a laminate.
  • gold nanorods (NRs) were added to poly- caprolactone (PCL) polymer, which polymer was then electrospun into layers.
  • the layers were then irradiated with a laser at 1 W of power at 770 nm wavelength for about 45 seconds at a distance of about 5 mm with a focusing filter in place.
  • the irradiation resulted in local fusion between adjacent layers.
  • a spinneret containing the polymeric fluid is oriented essentially perpendicular to the plane of the first rotating surface of the mandrel.
  • the spinneret may, in some embodiments, be oriented essentially parallel to an axis about which the first rotating surface of the mandrel rotates.
  • the spinneret need not be oriented exactly parallel to the mandrel's axis of rotation, and the spinnarent need not be aligned so that it is in register with the axis of rotation.
  • the spinneret may be aligned with a point that is at a radial distance from the center of the disc.
  • the spinneret may, of course, be aligned with the center of the disc.
  • the spinneret dispenses polymer so as to electrospin a fiber onto a rotating mandrel.
  • the mandrel suitably has an angular velocity, which in turn allows the fibers to align in a circumferential direction.
  • fibrous materials (which may be termed "scaffolds") formed according to these methods may have a spatially varying macrostructure.
  • the mandrel is suitably circular, although circulate mandrels are not necessary.
  • the surface of the mandrel also need not be perpendicular to the spinneret. Fibrous materials may be formed in an arrayed fashion, in which multiple mandrels rotate as multiple spinnarets dispense polymer onto the mandrels so as to simultaneously form fibrous layers on the mandrels.
  • the polymeric fibers may be formed of a polymer that is natural, synthetic, biocompatible, biodegradable, non-biodegradable, biosorbable, or any combination thereof, as described elsewhere herein. Fibers that comprise polycaprolactone are considered especially suitable.
  • a user may also deposit a cell or even a population of cells onto the electrospun fiber. It should be understood that this deposition is not limited to applying the cells to a surface of the fiber, as a user may contact or otherwise immerse the fiber into a cell-containing medium. Stem cells and other cells (including those cells described elsewhere herein) are all considered suitable for this application.
  • At least a portion of the mandrel surface onto which the fiber is electrospun suitably has a linear velocity during electrospinning of between about 8 m/s and about 12 m/s; linear velocities of about 10 m/s are considered especially suitable.
  • the polymeric fiber may be electrospun so as to form a body having at least one cross-sectional dimension in the range of from about 10 micrometers to about 1 cm, or from about 50 micrometers to about 0.5 cm.
  • Bodies formed according to these disclosed methods are suitably fibrous layers in form. The fibrous layers may then be cut to conform to a shape that a user desires.
  • the rotating surface of the mandrel comprises a first conductive region and a second conductive region separated by an insulating region disposed there between.
  • a pattern may be characterized as being a target or bulls-eye pattern.
  • These patters may be used to give rise to a plurality of polymeric fibers that are aligned radially relative to an axis about which the first rotating surface of the mandrel rotates.
  • These radially aligned fibers may then be disposed adjacent to fibers that have a arcuate (e.g, circumferential) alignment, with the radially aligned fibers acting as "tie fibers" relative to the arcuately aligned fibers.
  • compositions suitably include a first layer comprising a first population of polymeric fibers, the first population of polymeric fibers having an anisotropic alignment that varies spatially within the layer.
  • An exemplary material is shown in Figure 19B and Figure 19C, which figures show spatial variation of fiber alignment within a fibrous material.
  • At least a portion of the first population of polymeric fibers has an arcuate alignment; fibers having a circular or circumferential alignment are considered especially suitable.
  • At least a portion of the first population of fibers suitably has an average diameter in the range of from 10 nm to about 10 micrometers.
  • the population of fibers may contain a population of nanoscale bodies; suitable such bodies are described elsewhere herein.
  • compositions may also include a population of cells contacting the first population of fibers.
  • the cells may be stem cells, connective tissue cells, or other cells described elsewhere herein.
  • the polymeric fibers may be formed from materials that are natural, synthetic, biocompatible, biodegradable, non-biodegradable, and / or biosorbable, and unless specifically restricted to one or more of these categories, the fibers may comprise materials from any one of these categories.
  • compositions according to this disclosure may include a second fibrous layer, the second fibrous layer comprising a second population of fibers.
  • the second fibrous layer is suitably bonded to the first fibrous layer.
  • the second fibrous layer may comprise a second population of fibers having an average diameter in the range of from 10 nm to about 10 micrometers.
  • the second population of fibers may be aligned essentially parallel to one another. In some embodiments, the second population of fibers has an arcuate alignment.
  • the alignments of the first and second populations of fibers may be different; i.e., the the second population of fibers is aligned in a direction that differs from the alignment of the first population of fibers.
  • the second population of fibers may include a population of nanoscale bodies disposed within. Suitable such bodies are described elsewhere herein.
  • the compositions may include a porogenic material. The porogenic material may be disposed within the first layer, the second layer, or even both.
  • the porogenic materials may be used, as one example, to give rise to a material that includes anisotropically aligned fibers and also includes sufficient void space so allow for cell seeding or even cell ingrowth.
  • a use may form a fibrous layer from two electrospun polymer materials - a first material that is comparatively fast to degrade under certain conditions, and a second material that is slower to degrade under conditions that degrade the first material.
  • the user may form the desired layer from these two materials; by dispensing both materials from the same spinneret (or even from different spinnarets) and applying the methods disclosed herein, the user can create a fibrous layer that includes fibers of both materials, the fibers all sharing the same alignment.
  • the user may then expose the fibrous material to conditions that degrade the first material, the degradation of that first material in turn giving rise to void spaces within the fibrous layer. Cells may then be seeded into or grow into the void spaces left behind by the now-degraded first material.
  • the user may then, depending on their needs, install the seeded implant into a subject.
  • the second material of the implant may be chosen to degrade over time under physiological conditions so as to allow the subject's own cells to take the place of the second material as that material degrades, while still providing rigidity to the implant before
  • the second material may be one that does not degrade under physiological conditions.
  • the present disclosure also provides biocompatible implants.
  • implants suitably include a quantity of a composition described herein, e.g., a composition that has a first layer comprising a first population of polymeric fibers, the first population of polymeric fibers having an anisotropic alignment that varies spatially within the layer.
  • the quantity of material may be shaped so as to approximate at least a portion of a knee meniscus, at least a portion of an annulus fibrosis, or other fibrous tissue.
  • Examplary annulus fibrosis and meniscus tissues are shown in Figure 6 and Figure 8, which figures illustrate the fibrous, laminate structure within the tissues.
  • the present disclosure also provides methods, which method include seeding a composition described herein with a population of cells.
  • the cells may be autologous, non- autologous, or both.
  • the user may then implant the seeded composition into a subject.
  • Non-limiting figure 18 is illustrative of these methods.
  • a user may form one or more fibrous layers, which layers include fibers having an anisotropic alignment, and which fibers may also include nanoscale bodies.
  • the user may then cut the layers to shape.
  • the layers may be cut into crescent shapes and then fused to one another by application of laser radiation to the layers, which radiation in turn effects local heating and bonds the layers together.
  • the application of radiation may be performed in an arrayed fashion, where radiation is simultaneously applied to the fibrous layers at a variety of locations, e.g., by an array of lasers. Alternatively, radiation may be applied sequentially to a variety of locations.
  • the user may then "build up" a three-dimensional body that has an anatomic form and that also features arcuately aligned fibers within, the alignment of the fibers replicating the alignment of the fibers in naturally-occurring tissue.
  • the user may seed the layers with cells before, during, or even after the layers are bonded to one another so as to form the anatomic construct.
  • NR Gold nanorods
  • PCL poly(e-caprolactone)
  • 1 : 1 THF:DMF poly(e-caprolactone)
  • Optimization of NR concentration was carried out on 10mm x 10mm strips using a handheld IR laser (Chameleon Ti: sapphire laser, 770nms, LOW) distanced ⁇ 5 mm from the sample. IR light was focused through a ⁇ 1 mm diameter filter, and exposure time was set at -45 seconds.
  • Nanorod-containing scaffolds (NRS) and PCL-alone scaffolds (PCL) were sputter coated and viewed under SEM.
  • Fiber size was determined using ImageJ.
  • scaffolds were extended to failure at 0.1%/sec using an Instron 5848.
  • Laminates were formed by overlaying 20 x 10mm scaffold strips, with a 10 mm overlap region. Fusion of layers was accomplished (with one or two weld points) via a heated probe or via IR exposure as above. Laminates were extended to failure at a rate of 0.1%/sec, and maximum load of the interface recorded.
  • Bovine MSC viability and morphology was assessed on NRS with and without prior IR exposure via Live/Dead and Actin-DAPI staining through day 7. Statistical significance was determined by ANOVA with Tukey's post-hoc tests (p ⁇ 0.05).
  • Laminates were readily formed with IR exposure of NRS, with both one and two weld points (Figure 2). For both annealing methods, increasing weld number increased interface strength ( Figure 2), with spot welding via heated probe having ⁇ 2-3-fold higher strength than laser-mediated assembly (p ⁇ 0.05). Outside of the welds, cell number and morphology were similar for both methods (not shown). It should be understood that a user may irradiate adjacent layers at one, two, or more locations. [0114] NRs incorporated into electrospun PCL fibers did not substantially alter fiber morphology or scaffold mechanical properties, as shown in Figure 15. As shown by Figure 14, NR-irradiation welding retained more fibrous structure than did welding layers using a heated probe.
  • NRs Local heating of gold NRs could be achieved with focused application of IR light and by varying the concentration of NRs within the spinning solution. Inclusion of NRs within the fibers did not appear to alter cell viability or morphology after one week of culture. Consistent with the previous annealing method (heated probe), cell morphology was only perturbed within the weld area, suggesting normal fiber architecture outside the exposure site, (see Figure 14) Welds were capable of holding layers in apposition for a long enough period of time for cell colonization and matrix deposition to occur. As shown in Figure 16, nanorod-mediated infrared welding produced a stable interface, which interface had increasing mechanical properties with increasing weld number.
  • Nanofibrous scaffolds were created via electrospinning. Briefly, poly(e- caprolactone) (PCL) (80 kDa) was dissolved in equal parts dimethylformamide and
  • tetrahydrofuran (Fisher Chemical, Fairlawn, NJ) with constant stirring at 40 deg. C.
  • the polymer solution was driven through a 10 mL syringe attached to an 18G needle (the spinneret) via a syringe pump (KDS 100, KD Scientific, Holliston, MA) at 2 mL/h.
  • the spinneret was charged to +12 kV using a power supply (Gamma High Voltage Research Inc., Ormond Beach, FL) and placed ca. 150 mm away from a grounded mandrel to create an electric field and guide the resultant polymer jet towards the mandrel.
  • the mandrels were designed to produce a high surface velocity in different orientations, as fibers align along the direction of movement.
  • the spinneret was directed perpendicularly to the long axis of a cylindrical mandrel rotating at a linear surface velocity of 10 m/s.
  • the collection apparatus was modified such that the spinneret was centered above and perpendicular to the plane of a spinning thin aluminum collecting plate. In this configuration, the direction of movement is along the circumferential direction of the rotating circular surface. The plate was rotated such that a linear velocity of ca. 10 m/s was achieved at a radius of 30 mm.
  • Figure 3B illustrates the circumferential alignment of fibers as a function of the fibers' distance from the center of the rotating mandrel on which the fibrous body was formed.
  • CircAl specimens (p>0.01). Conversely, for long specimens, the modulus was 32-36% lower near the edge of the scaffolds compared to the center (p ⁇ 0.01). In terms of scaffold length, the modulus of the central region of the CircAl specimens was similar between short and long specimens (p>0.01); however, the modulus of the edge region for the short CircAl specimens was 68-90% higher than the respective long specimens (p ⁇ 0.01). No statistically significant differences could be detected between LinAl specimens as a result of varying specimen length or region within the scaffolds (p>0.05). These differences in modulus are further highlighted by a graphical depiction of the Lagrangian strain along the direction of loading (Figure 5C).
  • CircAl (P > 0.01) or LinAl scaffolds (P > 0.05). Similar results were obtained for the strain transverse to loading (Exx) (Table 1 in Figure 25). As a result, the Poisson's ratio was similar between all CircAl groups (P > 0.05) and between all LinAl groups (P > 0.05). Finally, the average shear strain (Exy) within the edge region of long CircAl specimens was 4-fold greater than that of the central region (Fig. 23E, P ⁇ 0.01). Again, no statistically significant differences were detected within
  • the disclosed methods allow for the construction of electrospun nanofibrous scaffolds with a spatially varying macroscopic fiber orientation. This orientation is similar to the meniscus. On the microscopic scale, these fibers were locally aligned, allowing alignment of MSCs (mesenchymal stem cells) similar to linearly aligned scaffolds.
  • MSCs meenchymal stem cells
  • the CircAl fibers followed a pattern roughly parallel to the circumferential direction of the disc, creating a linear gradient in fiber angle along the length of excised scaffolds and resulting in MSCs with a similar change in morphology over a macroscopic scale, in support of our hypothesis.
  • CircAl fiber scaffolds behaved similarly to linearly aligned scaffolds over a short spatial domain, but varied considerably as specimen length increased. Without being bound to any single theory, increasing the length of specimens for tensile testing may increase the frequency of CircAl fibers that enter and/or exit before reaching the clamped regions, resulting in greater regional differences within the scaffolds (i.e. decrease in modulus near the edge). These layers may be combined as shown in Figure 18 to generate anatomic 3D implants that recreate the macroscopic and microscopic features of the native tissue.
  • the organized nanofibrous scaffolds generated herein replicate the macroscopic curvature of the native tissue, and can direct the formation of an anatomic construct with direction dependent mechanical properties that vary across a large anatomic expanse.
  • Exemplary mechanical properties are shown in Figure 25 appended hereto.
  • the disclosed methodology preserved important features of nanofibrous scaffolds. Locally, a similar degree of fiber alignment was found when compared with a traditional electrospinning approach, as observed and quantified via SEM and bright field microscopy. Likewise, MSCs seeded on these scaffolds showed a similar local morphology, with the cytoskeleton and nucleus aligned with the fibers. Over a larger size scale, clear differences could be readily observed. CircAl fibers followed a pattern roughly parallel to the
  • An advantageB of electrospinning is the ability to create nanofibrous meshes that are instructive and direct cells to produce a locally aligned matrix.
  • CircAl mats occurs naturally and does not require additional handling or construction. Because this technology does not alter fundamental variables regarding electrospinning, it can be broadly applied to a wide range of polymers; the exemplary polymers mentioned herein do not limit the scope of the invention. Methods to introduce increased porosity by, e.g., simultaneously depositing a water-soluble fiber fraction or to further vary the mechanical properties by simultaneously spinning multiple polymers can likewise be applied to the disclosed technology.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention porte sur des matériaux fibreux et sur des stratifiés, lesquels comprennent des couches de fibres alignées de manière anisotrope, l'alignement de ces fibres pouvant être ajusté de façon à produire des fibres alignées de façon périphérique qui répliquent l'alignement de fibres d'un tissu fibreux natif, tel que le ménisque ou la fibrose annulaire. Des échafaudages de nanofibres alignés récapitulent une anisotropie mécanique. Dans des tissus naturels, des fibres à l'intérieur du tissu natif ont une forme de c prononcée, ou une organisation macroscopique en angle d'une autre façon. Pour répliquer ce changement d'organisation macroscopique sur la taille anatomique du ménisque, un procédé d'électrofilature collecte des fibres organisées sur un disque rotatif ou un mandrin rotatif. L'invention porte également sur des procédés, qui mettent en œuvre l'exposition à un rayonnement d'une première couche fibreuse comprenant une première population de fibres polymères ayant une première population de corps d'échelle nanométrique disposés à l'intérieur de celle-ci, l'exposition à un rayonnement étant effectuée de façon à lier au moins une partie de la première couche à une seconde couche fibreuse comprenant une seconde population de fibres polymères.
PCT/US2013/024313 2012-02-03 2013-02-01 Matériaux fibreux alignés présentant orientation de fibres variant dans l'espace et procédés associés WO2013116624A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594551P 2012-02-03 2012-02-03
US61/594,551 2012-02-03

Publications (1)

Publication Number Publication Date
WO2013116624A1 true WO2013116624A1 (fr) 2013-08-08

Family

ID=48905866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/024313 WO2013116624A1 (fr) 2012-02-03 2013-02-01 Matériaux fibreux alignés présentant orientation de fibres variant dans l'espace et procédés associés

Country Status (1)

Country Link
WO (1) WO2013116624A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044573A1 (fr) * 2015-09-08 2017-03-16 Clemson University Matériau biomimétique multicouche et procédé de formation
WO2018148722A1 (fr) 2017-02-13 2018-08-16 Rutgers, The State University Of New Jersey Échafaudage renforcé par filament polymère pour régénération partielle de ménisque
EP3628249A1 (fr) * 2014-12-26 2020-04-01 Ossio Ltd Implants médicaux biocomposites renforcés de fibres continues
US10869954B2 (en) 2016-03-07 2020-12-22 Ossio, Ltd. Surface treated biocomposite material, medical implants comprising same and methods of treatment thereof
US10869708B2 (en) 2014-09-07 2020-12-22 Ossio, Ltd. Anisotropic biocomposite material, medical implants comprising same and methods of treatment thereof
CN114507936A (zh) * 2020-10-28 2022-05-17 纳米及先进材料研发院有限公司 各向异性热传递性电磁干扰屏蔽复合材料和其制备方法
US11491264B2 (en) 2016-06-27 2022-11-08 Ossio Ltd. Fiber reinforced biocomposite medical implants with high mineral content

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040267362A1 (en) * 2003-06-30 2004-12-30 Julia Hwang Scaffold for connective tissue repair
US20070041952A1 (en) * 2005-04-18 2007-02-22 Duke University Three-dimensional fiber scaffolds for tissue engineering
US20070269481A1 (en) * 2006-01-27 2007-11-22 The Regents Of The University Of California Biomimetic Scaffolds
US20080176074A1 (en) * 2006-07-07 2008-07-24 Ilsoon Lee Asymmetric nanoparticles from polymer nanospheres
US20110066242A1 (en) * 2007-02-12 2011-03-17 The Trustees Of Columbia University In The City Of New York Biomimmetic nanofiber scaffold for soft tissue and soft tissue-to-bone repair, augmentation and replacement
US20110098826A1 (en) * 2009-10-28 2011-04-28 The Trustees Of The University Of Pennsylvania Disc-Like Angle-Ply Structures for Intervertebral Disc Tissue Engineering and Replacement

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040267362A1 (en) * 2003-06-30 2004-12-30 Julia Hwang Scaffold for connective tissue repair
US20070041952A1 (en) * 2005-04-18 2007-02-22 Duke University Three-dimensional fiber scaffolds for tissue engineering
US20070269481A1 (en) * 2006-01-27 2007-11-22 The Regents Of The University Of California Biomimetic Scaffolds
US20080176074A1 (en) * 2006-07-07 2008-07-24 Ilsoon Lee Asymmetric nanoparticles from polymer nanospheres
US20110066242A1 (en) * 2007-02-12 2011-03-17 The Trustees Of Columbia University In The City Of New York Biomimmetic nanofiber scaffold for soft tissue and soft tissue-to-bone repair, augmentation and replacement
US20110098826A1 (en) * 2009-10-28 2011-04-28 The Trustees Of The University Of Pennsylvania Disc-Like Angle-Ply Structures for Intervertebral Disc Tissue Engineering and Replacement

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869708B2 (en) 2014-09-07 2020-12-22 Ossio, Ltd. Anisotropic biocomposite material, medical implants comprising same and methods of treatment thereof
US11678923B2 (en) 2014-09-07 2023-06-20 Ossio, Ltd. Anisotropic biocomposite material, medical implants comprising same and methods of treatment thereof
US11730866B2 (en) 2014-12-26 2023-08-22 Ossio, Ltd. Continuous-fiber reinforced biocomposite medical implants
EP3628249A1 (fr) * 2014-12-26 2020-04-01 Ossio Ltd Implants médicaux biocomposites renforcés de fibres continues
US10926004B2 (en) 2014-12-26 2021-02-23 Ossio Ltd. Continuous-fiber reinforced biocomposite medical implants
US10695463B2 (en) 2015-09-08 2020-06-30 Clemson University Research Foundation Multi-layered biomimetic material and method of formation
WO2017044573A1 (fr) * 2015-09-08 2017-03-16 Clemson University Matériau biomimétique multicouche et procédé de formation
US10869954B2 (en) 2016-03-07 2020-12-22 Ossio, Ltd. Surface treated biocomposite material, medical implants comprising same and methods of treatment thereof
US11491264B2 (en) 2016-06-27 2022-11-08 Ossio Ltd. Fiber reinforced biocomposite medical implants with high mineral content
EP3579790A4 (fr) * 2017-02-13 2020-12-23 Rutgers, The State University of New Jersey Échafaudage renforcé par filament polymère pour régénération partielle de ménisque
US11116640B2 (en) 2017-02-13 2021-09-14 Rutgers, The State University Of New Jersey Polymer filament reinforced scaffold for partial meniscus regeneration
WO2018148722A1 (fr) 2017-02-13 2018-08-16 Rutgers, The State University Of New Jersey Échafaudage renforcé par filament polymère pour régénération partielle de ménisque
CN114507936A (zh) * 2020-10-28 2022-05-17 纳米及先进材料研发院有限公司 各向异性热传递性电磁干扰屏蔽复合材料和其制备方法
CN114507936B (zh) * 2020-10-28 2023-04-14 纳米及先进材料研发院有限公司 各向异性热传递性电磁干扰屏蔽复合材料和其制备方法

Similar Documents

Publication Publication Date Title
US20120265300A1 (en) Aligned Fibrous Materials With Spatially Varying Fiber Orientation and Related Methods
WO2013116624A1 (fr) Matériaux fibreux alignés présentant orientation de fibres variant dans l'espace et procédés associés
Chen et al. Direct writing electrospinning of scaffolds with multidimensional fiber architecture for hierarchical tissue engineering
Martins et al. Electrospun nanostructured scaffolds for tissue engineering applications
Ekaputra et al. Combining electrospun scaffolds with electrosprayed hydrogels leads to three-dimensional cellularization of hybrid constructs
US20110098826A1 (en) Disc-Like Angle-Ply Structures for Intervertebral Disc Tissue Engineering and Replacement
Koepsell et al. Tissue engineering of annulus fibrosus using electrospun fibrous scaffolds with aligned polycaprolactone fibers
Li et al. Low-voltage continuous electrospinning patterning
Mauck et al. Engineering on the straight and narrow: the mechanics of nanofibrous assemblies for fiber-reinforced tissue regeneration
Lee et al. Highly porous electrospun nanofibers enhanced by ultrasonication for improved cellular infiltration
Li et al. Nanofibrous polyhydroxyalkanoate matrices as cell growth supporting materials
Bosworth et al. Enhancing biocompatibility without compromising material properties: an optimised NaOH treatment for electrospun polycaprolactone fibres
EP1868660B1 (fr) Structure medicale d'accrochage, procedes de fabrication et d'utilisation de cette derniere
Bonani et al. Biohybrid nanofiber constructs with anisotropic biomechanical properties
Abel et al. Combination of electrospinning with other techniques for the fabrication of 3D polymeric and composite nanofibrous scaffolds with improved cellular interactions
Ndreu et al. Electrospun biodegradable nanofibrous mats for tissue engineering
Edwards et al. Design of nonwoven scaffold structures for tissue engineering of the anterior cruciate ligament
Woods et al. Electrospinning of biomimetic scaffolds for tissue-engineered vascular grafts: threading the path
Shalumon et al. Fabrication of three-dimensional nano, micro and micro/nano scaffolds of porous poly (lactic acid) by electrospinning and comparison of cell infiltration by Z-stacking/three-dimensional projection technique
Wu et al. Mechanically-enhanced three-dimensional scaffold with anisotropic morphology for tendon regeneration
Kang et al. Engineered three-dimensional nanofibrous multi-lamellar structure for annulus fibrosus repair
JP2016520328A (ja) 細胞または組織培養用の三次元構造
Hiremath et al. Melt blown polymeric nanofibers for medical applications-an overview
Abdal-Hay et al. Biocompatibility properties of polyamide 6/PCL blends composite textile scaffold using EA. hy926 human endothelial cells
Yoshida et al. Three-dimensional melt-electrowritten polycaprolactone/chitosan scaffolds enhance mesenchymal stem cell behavior

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13742906

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13742906

Country of ref document: EP

Kind code of ref document: A1